ClinicalTrials.gg
CompletedNCT05243628ABCUpdated Apr 8, 2025Results posted

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

A Phase 4 interventional study of Afrezza (insulin human) Inhalation Powder and insulin degludec in Type 1 Diabetes, sponsored by Mannkind Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Mannkind Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
22nd of 35
33 · median 74
Started
2022
the only one that year
Phase 4
4 of 35
none open now
Registered
33rd of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 22nd largest by enrollment, is the only one that started in 2022, is one of 4 in phase 4, and was the 33rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes

Read the detailed description

MKC-TI-192 is a Phase 4, 90-day, randomized, three-arm, multicenter clinical trial evaluating the treatment paradigm and efficacy of Afrezza in controlling postprandial glucose in adult subjects (≥18 years of age) with Type 1 Diabetes Mellitus (T1DM). Subjects will be randomized to one of three treatment groups (two Afrezza groups and one control group):

  • Afrezza + AID: Subjects in this group will use Afrezza for their bolus (mealtime) insulin and a continuous subcutaneous insulin infusion (CSII) pump with an automatic insulin delivery (AID) algorithm using rapid acting analogs (RAA) for their basal and correction insulin coverage.
  • Afrezza + Insulin Degludec: Subjects in this group will use Afrezza for their bolus (mealtime and correction) insulin and insulin degludec for basal insulin coverage.
  • AID Control: Subjects in this group will use a CSII pump with an AID algorithm using RAA for all bolus (mealtime and correction) and basal insulin coverage (control group).

The study is composed of up to 5 clinic visits (screening, 3 treatment visits, and an end-of-treatment visit) and 9 telephone visits.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Diabetes Mellitus
  • Insulin
  • Inhaled Insulin
  • Afrezza
  • Technosphere Insulin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥18 years of age at the time of signing the form
  • Clinical diagnosis of Type 1 Diabetes
  • ≥7.0% and \<11.0%
  • Treatment with a CSII pump with an AID algorithm (Medtronic 670G/770G or Tandem Control IQ) for at least 3 months
  • Ability to pay for their own RAA used in the insulin pump or injections, either through co-pay or self-pay, for the duration of the study
  • Willingness to follow study procedures including discontinuing their insulin pump and transitioning to insulin degludec injections plus Afrezza

Exclusion criteria

Exclusion Criteria:

  • A recent history of asthma (defined as using any medications to treat within the last year), (COPD), or any other pulmonary disease (e.g., cystic fibrosis, bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease
  • History of serious complications of diabetes (e.g., active proliferative retinopathy or symptomatic autonomic neuropathy)
  • History of to insulin or any of the Afrezza
  • On dialysis
  • Respiratory tract infection within 14 days before screening (subject may return 14 days after resolution of symptoms for rescreening)
  • Exposure to any drug in the past 30 days or an investigational device in the past 2 weeks
  • Adrenal insufficiency, active use of or planned steroid use
  • Hypothyroidism not controlled, as defined by thyroid stimulating hormone (TSH) outside the upper limit of the reference range by >1.5 × in the last 6 months, according to the local laboratory reference range
  • Hyperthyroidism not controlled, as defined by TSH below the normal reference range, according to the local laboratory
  • Use of antiadrenergic drugs (e.g., beta blockers and clonidine)
  • Any concurrent illness (other than diabetes mellitus) not controlled by a stable therapeutic regimen
  • History of a significant eating disorder (e.g., anorexia or bulimia nervosa)
  • Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the opinion of the Investigator or the Sponsor, would make the subject an unsuitable candidate for participation in the study
  • History of smoking (includes cigarettes, cigars, pipes, vaping devices, and marijuana) in the 6 months before screening
  • Female subject who is pregnant, breast-feeding, intends to become pregnant, or is of and not using adequate methods as required by local regulation or practice (may include sexual abstinence)
  • An event of severe hypoglycemia, as reported by the patient, within the last 180 days before screening
  • An episode of diabetic ketoacidosis (DKA), as determined by the Investigator, requiring hospitalization within the last 180 days before screening
  • Exposure to Afrezza in the 30 days before screening
  • Abnormal TSH or creatinine levels above 2.0 mg/dL
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Afrezza + Automatic Insulin Delivery

    Subjects in this group will use Afrezza for their bolus (mealtime) insulin and a CSII pump with an AID algorithm using RAA for their basal and correction insulin coverage.

    Biological: Afrezza (insulin human) Inhalation Powder · Device: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)

  • Experimental
    Afrezza + Insulin Degludec

    Subjects in this group will use Afrezza for their bolus (mealtime and correction) insulin and insulin degludec for basal insulin coverage.

    Biological: Afrezza (insulin human) Inhalation Powder · Biological: insulin degludec

  • Active comparator
    AID Control

    Subjects in this group will use a CSII pump with an AID algorithm using RAA for all bolus (mealtime and correction) and basal insulin coverage (control group).

    Device: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)

Interventions

  • Pharmaceutical form: powder Route of administration: inhalation

    Also known as: Technosphere Insulin

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

    Also known as: Tresiba

  • DeviceContinuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)

    Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in glycated hemoglobin (HbA1c) from baseline to end of study

    Time frame: 90 days

Secondary outcomes

  1. Events of Level 1 Hypoglycemia (SMBG < 70mg/dL)

    Events of hypoglycemia (SMBG \<70 mg/dL for SMBG values more than 30 minutes apart)

    Time frame: 90 days

  2. Events of Level 2 Hypoglycemia (SMBG < 54 mg/dL)

    Events of hypoglycemia (SMBG \<54 mg/dL for SMBG values more than 30 minutes apart)

    Time frame: 90 days

  3. Events of Severe Hypoglycemia

    Events of severe hypoglycemia requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions

    Time frame: 90 days

  4. Change in Time in Range (Glucose of 70 - 180 mg/dL)

    Change from baseline to end of study in Time in Range (TIR), defined as the percentage of time spent with glucose in the range of 70 to 180 mg/dL, based on continuous glucose monitoring derived glucose values

    Time frame: baseline and 90 days

  5. Change in Time Below Range (Glucose <70 mg/dL)

    Change from baseline to end of study in Time Below Range (TBR), defined as the percentage of time spent with glucose \<70 mg/dL, based on continuous glucose monitoring derived glucose values

    Time frame: baseline and 90 days

  6. Change in Percentage of Time With Glucose <54 mg/dL

    Change from baseline to end of study in percentage of time spent with glucose \<54 mg/dL, based on continuous glucose monitoring derived glucose values

    Time frame: baseline and 90 days

  7. Change in Time Above Range (Glucose >180 mg/dL)

    Change from baseline to end of study in Time Above Range (TAR), defined as the percentage of time spent with glucose \>180 mg/dL, based on continuous glucose monitoring derived glucose values

    Time frame: baseline and 90 days

  8. Change in Percentage of Time With Glucose >250 mg/dL

    Change from baseline to end of study in percentage of time spent with glucose \>250 mg/dL, based on continuous glucose monitoring derived glucose values

    Time frame: baseline and 90 days

  9. Change in Coefficient of Variation (CV)

    Change from baseline to end of study in glycemic variability as measured by coefficient of variation (CV), based on continuous glucose monitoring derived glucose values

    Time frame: baseline and 90 days

Other outcomes

  1. Change in Percent Predicted Forced Expiratory Volume in 1 Second

    Change in percent predicted forced expiratory volume in 1 second (FEV1) from baseline to end of study

    Time frame: baseline and 90 days

  2. Total Number of Treatment-Emergent Adverse Events

    Total Number of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: 90 days

  3. Total Number of Serious Adverse Events

    Total Number of Serious Adverse Events (SAEs)

    Time frame: 90 days

  4. Total Number of Adverse Events of Special Interest

    Total Number of Adverse Events of Special Interest (AESIs)

    Time frame: 90 days

  5. Total Number of Device Complaints

    Total Number of Device Complaints

    Time frame: 90 days

07

Results

Posted Oct 18, 2024
Limitations and caveats
Limitations of the study include its open-label and non-controlled study design and a small sample size (Total Started=28).

Participant flow

Participant flow — Overall Study
MilestoneAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Started13105
Completed9105
Not completed400

Outcome measures

PrimaryChange in HbA1c

Change in glycated hemoglobin (HbA1c) from baseline to end of study

Time frame:
90 days
Reported as:
Mean · percent of glycated hemoglobin
Change in HbA1c
percent of glycated hemoglobinAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Change in HbA1c0.32 ± 0.550.35 ± 0.580.52 ± 0.29
SecondaryEvents of Level 1 Hypoglycemia (SMBG < 70mg/dL)

Events of hypoglycemia (SMBG \<70 mg/dL for SMBG values more than 30 minutes apart)

Time frame:
90 days
Reported as:
Mean · Count of events
Events of Level 1 Hypoglycemia (SMBG < 70mg/dL)
Count of eventsAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Events of Level 1 Hypoglycemia (SMBG < 70mg/dL)12 ± 1220 ± 1214 ± 7
SecondaryEvents of Level 2 Hypoglycemia (SMBG < 54 mg/dL)

Events of hypoglycemia (SMBG \<54 mg/dL for SMBG values more than 30 minutes apart)

Time frame:
90 days
Reported as:
Mean · Count of events
Events of Level 2 Hypoglycemia (SMBG < 54 mg/dL)
Count of eventsAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Events of Level 2 Hypoglycemia (SMBG < 54 mg/dL)3 ± 35 ± 44 ± 5
SecondaryEvents of Severe Hypoglycemia

Events of severe hypoglycemia requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions

Time frame:
90 days
Reported as:
Number · Count of events
Events of Severe Hypoglycemia
Count of eventsAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Events of Severe Hypoglycemia000
SecondaryChange in Time in Range (Glucose of 70 - 180 mg/dL)

Change from baseline to end of study in Time in Range (TIR), defined as the percentage of time spent with glucose in the range of 70 to 180 mg/dL, based on continuous glucose monitoring derived glucose values

Time frame:
baseline and 90 days
Reported as:
Mean · percent of TIR
Change in Time in Range (Glucose of 70 - 180 mg/dL)
percent of TIRAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Change in Time in Range (Glucose of 70 - 180 mg/dL)4.69 ± 27.61-3.89 ± 16.001.99 ± 10.12
SecondaryChange in Time Below Range (Glucose <70 mg/dL)

Change from baseline to end of study in Time Below Range (TBR), defined as the percentage of time spent with glucose \<70 mg/dL, based on continuous glucose monitoring derived glucose values

Time frame:
baseline and 90 days
Reported as:
Mean · percent of TBR
Change in Time Below Range (Glucose <70 mg/dL)
percent of TBRAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Change in Time Below Range (Glucose <70 mg/dL)-0.06 ± 1.721.92 ± 4.23-0.18 ± 0.44
SecondaryChange in Percentage of Time With Glucose <54 mg/dL

Change from baseline to end of study in percentage of time spent with glucose \<54 mg/dL, based on continuous glucose monitoring derived glucose values

Time frame:
baseline and 90 days
Reported as:
Mean · percent of time with glucose <54mg/dL
Change in Percentage of Time With Glucose <54 mg/dL
percent of time with glucose <54mg/dLAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Change in Percentage of Time With Glucose <54 mg/dL0.03 ± 0.430.88 ± 2.04-0.1 ± 0.12
SecondaryChange in Time Above Range (Glucose >180 mg/dL)

Change from baseline to end of study in Time Above Range (TAR), defined as the percentage of time spent with glucose \>180 mg/dL, based on continuous glucose monitoring derived glucose values

Time frame:
baseline and 90 days
Reported as:
Mean · percent of TAR
Change in Time Above Range (Glucose >180 mg/dL)
percent of TARAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Change in Time Above Range (Glucose >180 mg/dL)-4.63 ± 28.691.97 ± 17.89-1.81 ± 10.17
SecondaryChange in Percentage of Time With Glucose >250 mg/dL

Change from baseline to end of study in percentage of time spent with glucose \>250 mg/dL, based on continuous glucose monitoring derived glucose values

Time frame:
baseline and 90 days
Reported as:
Mean · percent of time with glucose >250mg/dL
Change in Percentage of Time With Glucose >250 mg/dL
percent of time with glucose >250mg/dLAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Change in Percentage of Time With Glucose >250 mg/dL-1.04 ± 23.570.84 ± 9.86-4.47 ± 3.03
SecondaryChange in Coefficient of Variation (CV)

Change from baseline to end of study in glycemic variability as measured by coefficient of variation (CV), based on continuous glucose monitoring derived glucose values

Time frame:
baseline and 90 days
Reported as:
Mean · percent of coefficient of variation
Change in Coefficient of Variation (CV)
percent of coefficient of variationAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Change in Coefficient of Variation (CV)1 ± 54 ± 9-5 ± 3
Other pre-specifiedChange in Percent Predicted Forced Expiratory Volume in 1 Second

Change in percent predicted forced expiratory volume in 1 second (FEV1) from baseline to end of study

Time frame:
baseline and 90 days
Reported as:
Mean · percent predicted FEV1
Change in Percent Predicted Forced Expiratory Volume in 1 Second
percent predicted FEV1Afrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Change in Percent Predicted Forced Expiratory Volume in 1 Second-2 ± 52 ± 6-2 ± 6
Other pre-specifiedTotal Number of Treatment-Emergent Adverse Events

Total Number of Treatment-Emergent Adverse Events (TEAEs)

Time frame:
90 days
Reported as:
Number · count of TEAEs
Total Number of Treatment-Emergent Adverse Events
count of TEAEsAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Total Number of Treatment-Emergent Adverse Events26121
Other pre-specifiedTotal Number of Serious Adverse Events

Total Number of Serious Adverse Events (SAEs)

Time frame:
90 days
Reported as:
Number · count of SAEs
Total Number of Serious Adverse Events
count of SAEsAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Total Number of Serious Adverse Events210
Other pre-specifiedTotal Number of Adverse Events of Special Interest

Total Number of Adverse Events of Special Interest (AESIs)

Time frame:
90 days
Reported as:
Number · count of AESIs
Total Number of Adverse Events of Special Interest
count of AESIsAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Total Number of Adverse Events of Special Interest300
Other pre-specifiedTotal Number of Device Complaints

Total Number of Device Complaints

Time frame:
90 days
Reported as:
Number · Count of Device Complaints
Total Number of Device Complaints
Count of Device ComplaintsAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Total Number of Device Complaints000

Adverse events

Collected over Adverse Event data were collected for a period of up to 120 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Afrezza + Automatic Insulin Delivery (AID)0/13 (0%)2/13 (15.4%)7/13 (53.8%)
Afrezza + Insulin Degludec0/10 (0%)1/10 (10%)8/10 (80%)
AID Control0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent serious events
Most frequent serious events
EventAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
Localised infectionInfections and infestations0/131/100/5
Diabetic KetoacidosisMetabolism and nutrition disorders1/130/100/5
Angina pectorisCardiac disorders1/130/100/5
Most frequent other events
Showing 10 of 26
Most frequent other events
EventAfrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID Control
COVID-19 respiratory infectionInfections and infestations4/134/100/5
SinusitisInfections and infestations0/130/101/5
CoughRespiratory, thoracic and mediastinal disorders2/130/100/5
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/130/100/5
VomitingGastrointestinal disorders1/131/100/5
Urinary Tract InfectionInfections and infestations0/131/100/5
CellulitisInfections and infestations0/131/100/5
LaryngitisInfections and infestations0/131/100/5
NauseaGastrointestinal disorders1/131/100/5
AnxietyPsychiatric disorders0/131/100/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Afrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID ControlTotal
<=18 years0000
Between 18 and 65 years1310528
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Afrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID ControlTotal
Female79319
Male6129
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Afrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID ControlTotal
Hispanic or Latino3003
Not Hispanic or Latino1010525
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Afrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID ControlTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White1310528
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Afrezza + Automatic Insulin Delivery (AID)Afrezza + Insulin DegludecAID ControlTotal
United States1310528
08

Study locations

2 sites
  • Diabetes Treatment Center, Loma Linda University
    Loma Linda, California 92354, United States
  • Texas Diabetes and Endocrinology
    Austin, Texas 78731, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Oct 2022, 6 months.

Results were first posted in Oct 2024, 2 years after primary completion.

Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Feb 17, 2022
StartActual
Mar 31, 2022
Primary completionActual
Oct 17, 2022
CompletionActual
Oct 17, 2022
Results first posted
Oct 18, 2024
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05243628
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Mar 31, 2022
Primary completion
Oct 17, 2022
Completion
Oct 17, 2022
Results posted
Oct 18, 2024
Last update
Apr 8, 2025

Study contacts

Kevin Kaiserman, MD
study director · Mannkind Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin, Regular, Human · Insulin degludec

Start the discussion